Zobrazeno 1 - 10
of 49
pro vyhledávání: '"I. N. Subortseva"'
Autor:
A. L. Melikyan, I. N. Subortseva
Publikováno v:
Онкогематология, Vol 17, Iss 4, Pp 60-66 (2022)
Externí odkaz:
https://doaj.org/article/11d33757045b45d38da88bb22dfc9e13
Publikováno v:
Бюллетень сибирской медицины, Vol 20, Iss 2, Pp 239-244 (2021)
The article presents a clinical case of comorbid pathology – development of migraine against the background of systemic mastocytosis. The classification and clinical manifestations of systemic mastocytosis, a rare blood disease, are given.This clin
Externí odkaz:
https://doaj.org/article/92b34d42572a433cb80d42f8620f18cd
Autor:
A. L. Melikyan, I. N. Subortseva, E. A. Gilyazitdinova, T. I. Koloshejnova, E. K. Egorova, E. I. Pustovaya, A. B. Sudarikov, A. O. Abdullaev, L. A. Gorgidze, D. I. Chebotarev
Publikováno v:
Терапевтический архив, Vol 92, Iss 7, Pp 95-99 (2020)
Primary myelofibrosis is a myeloproliferative neoplasm that occurs de novo, characterized by clonal proliferation of stem cells, abnormal expression of cytokines, bone marrow fibrosis, hepatosplenomegaly as a result of extramedullary hematopoiesis, s
Externí odkaz:
https://doaj.org/article/c76c7b7e9a0b424fa8e1fe9422cfda33
Autor:
A. L. Melikyan, E. I. Pustovaya, E. K. Egorova, M. V. Kalinina, T. I. Kolosheynova, I. N. Subortseva, E. A. Gilyazitdinova, V. N. Dvirnyk
Publikováno v:
Онкогематология, Vol 12, Iss 1, Pp 78-87 (2017)
The article presents a systematic diagnostic approach for thrombocytopenia, as well as the results of practical implementation of thrombocytopenia diagnostic protocol in adult patients. Among 183 patients first admitted to HRC with unspecified origin
Externí odkaz:
https://doaj.org/article/f636fc4f30cf4f61b11ce928e4446318
Autor:
M. M. Tanashyan, P. I. Kuznetsova, O. V. Lagoda, A. A. Shabalina, I. N. Subortseva, A. L. Melikyan
Publikováno v:
Анналы клинической и экспериментальной неврологии, Vol 8, Iss 2, Pp 41-45 (2017)
Myeloproliferative diseases (MPD) comprise a group of clonalpathology resulting from genetic alterations at a stem cell level.WHO (2008) divides MPD into several classical forms polycythemiavera, essential thrombocytemia, and primary myelofibrosis.Ha
Externí odkaz:
https://doaj.org/article/24f4c4f9443445adafa9d23b4fa282ab
Autor:
I. N. Subortseva, A. I. Melikyan
Publikováno v:
Онкогематология, Vol 11, Iss 4, Pp 8-17 (2017)
Chronic myeloid malignancies that have characteristics of both the myelodysplastic and myeloproliferative disorders allocated to myelodysplastic/myeloproliferative diseases (MDS/MPD) group in 2008 World Health Organization classification. This group
Externí odkaz:
https://doaj.org/article/3f8b43ddfe7041ecbe9ba365d3baf45b
Autor:
E. A. Domonova, A L Melikyan, EK Egorova, D. I. Chebotarev, O. Y. Silveystrova, Alla M. Kovrigina, I N Subortseva
Publikováno v:
Russian journal of hematology and transfusiology. 66:433-444
Introduction. Kaposi’s sarcoma (КS) is a multi-focal malignant tumor of vascular origin with a predominant lesion of the skin, involving internal organs and lymph nodes. Epidemic and immunosuppressive variants of the disease are considered to be t
Autor:
V A Vasilyeva, Elmira I. Kolgaeva, I N Subortseva, Z V Konova, Dmitry I. Chebotarev, T V Gaponova, Mariya V. Dovydenko, Alla M. Kovrigina, Valerii G. Savchenko, Larisa A. Kuzmina, Anait L. Melikyan, Elena N. Parovichnikova, Mikhail Yu. Drokov, Denis V. Kamelskih, Sokolova Ma, Mikhail Maschan
Publikováno v:
Терапевтический архив, Vol 93, Iss 7, Pp 805-810 (2021)
Indications of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with primary myelofibrosis are intermediate-2 and high-risk group of DIPSS (Dynamic International Prognostic Scoring System), beginning of the disease in childh
Autor:
Elena V. Morozova, A.Yu. Zaritskey, A L Melikyan, I N Subortseva, O.Yu. Vinogradova, Elza Lomaia, Larisa A. Kuzmina, Vasily Shuvaev
Publikováno v:
Clinical oncohematology. 14:129-137
Classical Ph-negative myeloproliferative neoplasms (MPN) constitute a group of diseases including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Over the past decade, the approaches to understanding of MPN pathogenesis and t
Autor:
A L Melikyan, I N Subortseva
Publikováno v:
Clinical oncohematology. 14:355-360
The issues of therapy response criteria, first-line hydroxy-carbamide intolerance and resistance to it as well as early changes in treatment strategy remain controversial and debatable in the management of polycythemia vera patients. The review outli